# Fasturtec TLS Treatment / Prophylysis

> **NCT00651911** · PHASE4 · COMPLETED · sponsor: **Sanofi** · enrollment: 45 (actual)

## Conditions studied

- Tumor Lysis Syndrome

## Interventions

- **DRUG:** urate oxidase

## Key facts

- **NCT ID:** NCT00651911
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-07
- **Primary completion:** —
- **Final completion:** 2004-07
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2008-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00651911

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00651911, "Fasturtec TLS Treatment / Prophylysis". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT00651911. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*